In short
NAVENIBART is an investigational drug currently being evaluated in clinical trials for the prevention of attacks in people with Hereditary Angioedema (HAE). This rare genetic condition causes episodes of severe swelling in various parts of the body. A Phase 3 clinical trial is currently assessing different dosing regimens of NAVENIBART given as subcutaneous injections to determine its safety and effectiveness compared to placebo. The study aims to evaluate how well NAVENIBART reduces the frequency of HAE attacks and improves quality of life for both adult and adolescent participants with type 1 or type 2 HAE.
Key points
- NAVENIBART is being investigated in a Phase 3 clinical trial for preventing Hereditary Angioedema (HAE) attacks, a rare genetic condition causing painful and potentially dangerous swelling episodes. The study evaluates different dosing regimens of NAVENIBART given as subcutaneous injections in both adults and adolescents with type 1 or 2 HAE. Researchers are primarily measuring the reduction in HAE attack frequency over six months compared to placebo, while also examining effects on attack severity, need for rescue medications, and quality of life improvements. Multiple dosing schedules are being tested, including 600 mg every 3 or 6 months, and an initial 600 mg dose followed by 300 mg maintenance doses every 3 months.
At a glance
- Drug Name
- NAVENIBART (also known as STAR-0215)
- Study Type
- Phase 3, multicenter, randomized, double-blind, placebo-controlled trial
- Condition
- Hereditary Angioedema (HAE) Types 1 and 2
- Administration
- Subcutaneous injection
- Adult Dosing Regimens
- • 600 mg every 3 months; • 600 mg initial dose followed by 300 mg every 3 months; • 600 mg every 6 months; • Placebo every 3 months (control group)
- Adolescent Dosing
- 600 mg initial dose followed by 300 mg every 3 months
- Primary Outcome
- Number of HAE attacks during the 6-month treatment period
- Key Secondary Outcomes
- • Reduction in moderate/severe attacks; • Reduction in attacks requiring on-demand treatment; • Percent reduction in monthly attacks; • Time to first attack; • Number of participants with significant attack reduction; • Participants with no attacks; • Quality of life improvements
- Safety Assessment
- Monitoring of treatment-emergent adverse events for approximately one year
Understanding Hereditary Angioedema (HAE)
Hereditary Angioedema is a rare genetic condition that causes episodes of severe swelling in various parts of the body. These swelling attacks can affect the hands, feet, face, genitals, airway, or intestinal tract. HAE attacks can be painful, disfiguring, and in cases where the airway is affected, potentially life-threatening. The condition is typically categorized as Type 1 or Type 2 HAE, both of which are being studied in the Navenibart clinical trial.
How is Navenibart Administered?
Navenibart is administered as a subcutaneous injection, which means it is injected under the skin. This administration method allows patients to potentially receive the medication outside of a medical facility, though the current study is examining the drug in a controlled clinical setting.
Dosing Regimens Being Studied
The current clinical trial is testing several different dosing schedules to determine which might be most effective:
- Dosing Regimen 1 for Adults: 600 mg of navenibart every 3 months
- Dosing Regimen 2 for Adults: 600 mg of navenibart on Day 1, followed by 300 mg every 3 months starting at month 3
- Dosing Regimen 3 for Adults: 600 mg of navenibart every 6 months
- Regimen for Adolescents: 600 mg of navenibart on Day 1, followed by 300 mg every 3 months starting at month 3
Some adult participants in the study will receive a placebo instead of navenibart to help researchers accurately measure the drug's effectiveness.
Current Clinical Research
Navenibart is being studied in a Phase 3 clinical trial, which is typically one of the final stages of testing before a medication might be approved for general use. This particular study is described as multicenter (conducted at multiple medical facilities), randomized (participants are assigned to treatment groups by chance), double-blind (neither participants nor researchers know who is receiving the actual drug versus placebo), and placebo-controlled (comparing the drug to an inactive substance).
The study includes both adult and adolescent participants with type 1 or type 2 HAE. Adult participants are randomly assigned to one of four treatment groups, while adolescent participants all receive the same navenibart regimen.
How Effectiveness is Being Measured
Researchers are measuring several outcomes to determine if navenibart is effective:
- Primary outcome: The number of HAE attacks during the 6-month treatment period. These attacks are confirmed by investigators and normalized for time.
- Secondary outcomes include:
- Number of moderate or severe HAE attacks
- Number of HAE attacks requiring on-demand treatment
- Percent reduction in monthly HAE attacks compared to the pre-treatment period
- Time until the first HAE attack after receiving doses
- Number of participants who have a significant reduction (50%, 70%, or 90%) in HAE attacks
- Number of participants with no HAE attacks during treatment
These measurements will help determine how well navenibart prevents HAE attacks and whether certain dosing regimens are more effective than others.
Safety Monitoring
As with any clinical trial, the safety of navenibart is being closely monitored. Researchers are tracking treatment-emergent adverse events, which are any unfavorable or unintended signs, symptoms, or diseases that occur during the study period. This monitoring will continue for nearly a full year (through day 361) to identify any potential side effects or safety concerns.
Impact on Quality of Life
Beyond just preventing attacks, researchers are also interested in how navenibart might improve patients' overall quality of life. The study is using the Angioedema Quality of Life questionnaire, a specialized survey designed to measure how HAE affects a person's daily life and well-being. Changes in scores on this questionnaire from the beginning to the end of the study will help determine if navenibart improves patients' quality of life.